[Peptide imunofan and moxifloxacin combined effects on toxigenic strain Clostridium difficile in vitro.]

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Clostridium difficile infection (CDI) is a significant healthcare concern.
• Understanding the in vitro interactions between antibiotics and novel antimicrobial agents is crucial for effective treatment strategies.

Purpose of the Study:

• To investigate the in vitro antimicrobial activity of the imunofan peptide against Clostridium difficile.
• To analyze the combined effects of the imunofan peptide and moxifloxacin on C. difficile growth rates.

Main Methods:

• In vitro analysis of Clostridium difficile growth rates.
• Determination of antimicrobial activity of imunofan peptide at various concentrations (0.05, 0.25 μg/ml).
• Evaluation of combined effects of imunofan peptide and moxifloxacin (0-1.5 MIC) on bacterial growth.

Main Results:

• The imunofan peptide demonstrated antimicrobial properties against a toxigenic C. difficile strain at concentrations of 0.05 and 0.25 μg/ml.
• Moxifloxacin, at concentrations ranging from 0 to 1.5 Minimum Inhibitory Concentrations (MIC), stimulated C. difficile growth when combined with the peptide, irrespective of imunofan concentration.
• Maximum growth inhibition was observed with the combined use of imunofan peptide (1.5 μg/ml) and moxifloxacin (2.5 MIC).

Conclusions:

• The imunofan peptide possesses intrinsic antimicrobial activity against Clostridium difficile.
• The combination of moxifloxacin and the imunofan peptide can lead to paradoxical growth stimulation of C. difficile at sub-inhibitory concentrations of the antibiotic.
• Specific concentrations of both agents are required to achieve maximal growth inhibition of C. difficile in vitro.